Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Regulation of the Cardiovascular System

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fetal Echocardiographic Features for the Prediction of the Development of Aortic Coarctation in the Perinatal Period.

Journal of clinical ultrasound : JCU·2026

Same author

Longitudinal Characterization of Immune Response in a Cohort of Children Hospitalized with Multisystem Inflammatory Syndrome.

Children (Basel, Switzerland)·2023

Same author

Cardiac MRI in midterm follow-up of MISC: a multicenter study.

European journal of pediatrics·2022

Same author

Authorship: From credit to accountability. Reflections from the Editors' Network.

Revista portuguesa de cardiologia·2019

Same author

Authorship: From Credit to Accountability Reflections From the Editors´ Network.

Anatolian journal of cardiology·2019

Same author

Authorship: from credit to accountability. Reflections from the Editors' Network.

Clinical research in cardiology : official journal of the German Cardiac Society·2019

Search research articles

Related Experiment Video

Updated: May 28, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Endocannabinoids and cardiovascular prevention: real progress?

Savina Nodari¹, Alessandra Manerba, Marco Metra

¹Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia - Italy.

Heart International

|October 7, 2011

Summary

Obesity is a growing global health crisis linked to cardiovascular disease. Targeting the endocannabinoid system, particularly with CB1 receptor antagonists, shows promise for weight management and improving metabolic health in obese patients.

Keywords:

CB1 antagonists Endocannabinoid system Obesity

More Related Videos

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Area of Science:

Endocrinology
Cardiovascular Medicine
Pharmacology

Background:

Obesity prevalence is increasing globally, contributing significantly to cardiovascular morbidity and mortality.
Central obesity is a major modifiable risk factor for coronary heart disease, increasing risks of stroke, heart failure, and myocardial infarction.
Lifestyle modifications are primary treatments for obesity, but pharmacological interventions are often necessary for high-risk individuals.

Purpose of the Study:

To explore the role of the endocannabinoid system in regulating food intake and energy balance.
To investigate the potential of targeting the endocannabinoid system as a novel therapeutic strategy for obesity and associated metabolic disorders.

Main Methods:

Review of recent studies on the endocannabinoid system and its involvement in obesity.
Analysis of data from clinical trials using CB1 receptor antagonists, such as rimonabant.
Evaluation of the effects of endocannabinoid system antagonism on body weight, fat distribution, and metabolic factors.

Main Results:

The endocannabinoid system plays a crucial role in controlling food intake and energy balance.
CB1 receptor antagonists like rimonabant have demonstrated significant reductions in body weight and waist circumference.
Treatment with CB1 antagonists improved key metabolic factors, including cholesterol, triglycerides, and blood glucose levels.

Conclusions:

The endocannabinoid system presents a promising new target for the management of obesity.
Antagonism of the endocannabinoid system may offer a viable treatment option for overweight and obese patients at high cardiovascular risk.
Further confirmation of these findings could lead to new pharmacological therapies for obesity and metabolic syndrome.